# Psychoeducation in families of children with attention deficit hyperactivity disorder (ADHD) in Spain

Submission date	Recruitment status	Prospectively registered
30/01/2010	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
24/02/2010	Completed	☐ Results
Last Edited	<b>Condition category</b> Mental and Behavioural Disorders	Individual participant data
24/02/2010		Record updated in last year

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Maite Ferrin

#### Contact details

Fundacion para la Investigacion Biosanitaria de Andalucia Oriental (FIBAO) Dr Azpitarte 4, Edificio Licinio de la Fuente, 4ª planta Granada Spain 18014 +34 958 02 02 45

# Additional identifiers

**EudraCT/CTIS** number

maiteferrin@yahoo.es

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

# Study information

#### Scientific Title

Psychoeducation in families of children with attention deficit hyperactivity disorder (ADHD) in Spain: evaluation of the efficacy in a randomised controlled trial

## Study objectives

- 1. Psychoeducation intervention in families of attention deficit hyperactivity disorder (ADHD) children/adolescents will lead to a significant reduction of ADHD symptoms in these children in comparison with a control group
- 2. Psychoeducation intervention in families of ADHD children/adolescents will lead to improvement of treatment adherence rates in these children in comparison with a control group 3. Psychoeducation intervention in families of ADHD children/adolescents will lead to improvement of quality of life in these families in comparison with a control group

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Local medical ethics committee (Complejo Hospitalario de Jaen, Spain) approved in September 2007

# Study design

Single centre randomised controlled double-blind parallel group trial

# Primary study design

Interventional

# Secondary study design

Randomised controlled trial

# Study setting(s)

Hospital

# Study type(s)

Treatment

# Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

# Health condition(s) or problem(s) studied

Attention deficit disorder (ADD)/attention deficit hyperactivity disorder (ADHD)

#### **Interventions**

Psychoeducation intervention (experimental group):

Families of ADHD children/adolescents attending psychoeducation sessions. Psychoeducation provided by Child and Adolescent Psychiatrist and consisting of 12 weekly sessions, 90 minutes length, groups of 8 - 10 families.

#### Sessions organisation:

- 1. 10 20 minutes: "warm-up" period, informal conversation, doubts from the previous session
- 2. 30 35 minutes: lecture on the topic
- 3. 10 minutes: brief pause
- 4. 30 40 minutes: topic discussion

Participants encouraged to ask and make comments.

#### Psychoeducation program for ADHD:

Session 1: Presentations and group functioning rules. What is ADHD?

Session 2: Core symptoms. Diagnostic procedures

Session 3: Etiological, maintaining and perpetuating factors

Session 4: Comorbidities in ADHD

Session 5: Prognosis and outcome: ADHD in the adolescent and the adult

Session 6: Executive function

Session 7: Pharmacological treatments: stimulants and non-stimulants

Session 8: Diets and other treatments

Session 9: Cognitive behavioural treatment and other management approaches

Session 10: Dealing with everyday-life problems at home I

Session 11: Dealing with everyday-life problems at home II

Session 12: Dealing with everyday-life problems at school

Session 13: Summarising, final questions and doubts. Closing down session.

#### Support group (active control group):

Families of ADHD children/adolescents. Parents attending 12 weekly sessions, 90 minutes length, groups of 8 - 10 families, non-structured support groups provided by the same Child and Adolescent Psychiatrist. Control group only differs on the educational content provided.

# Intervention Type

Other

#### Phase

Not Applicable

#### Primary outcome measure

ADHD-symptoms by Conners Scale, measured at baseline, 12 weeks, 6 months, 9 months, and 15 months

#### Secondary outcome measures

- 1. Attitudes Towards Treatment Questionnaire (QATT)
- 2. Adherence levels measured by direct questioning to families and pill counting (integrated into a composite)
- 3. Psychiatric conditions: Strengths and Difficulties Questionnaire (SDQ)
- 4. Children's Global Assessment Scale (C-GAS)
- 5. Clinical Global Impression (CGI)
- 6. Quality of life by PedsQL™ Core Version 4 and Cognitive Scale
- 7. Satisfaction with psychoeducation program by the Consumer Satisfaction Questionnaire
- 8. Parents Stress Index (PSI), 3th Edition

Assessments on all measures pre-treatment and post-treatment. Follow-up assessment on all measures after 3 months, 6 months and 12 months.

## Overall study start date

01/09/2009

# Completion date

01/09/2010

# Eligibility

#### Key inclusion criteria

- 1. Diagnosis of attention deficit disorder (ADD)/ADHD in child (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition [DSM-IV]), with most of their co-morbidity represented (except for the exclusion criteria), and any treatment prescribed
- 2. Age of child between 3 and 19 years, either sex
- 3. Informed consent of the parents and the children available
- 4. Parents' age greater than or equal to 18 years
- 5. Responsibility and legal capacity in parents
- 6. Participant on clinical ADHD symptoms stabilisation for at least 1 month before entering the study (with or without medical treatment)

## Participant type(s)

Patient

#### Age group

Child

# Lower age limit

18 Years

#### Sex

Both

# Target number of participants

70 (35 intervention group, 35 control group)

# Key exclusion criteria

- 1. Severe Autistic Spectrum Disorders (\*)
- 2. Severe learning disabilities (\*)
- 3. Earlier or current participation in other intervention trials that might interfere with the current study
- (\*) due to added problems to ADHD, thus requiring a different sort of intervention

#### Date of first enrolment

01/09/2009

#### Date of final enrolment

01/09/2010

# Locations

#### Countries of recruitment

Spain

# Study participating centre

Fundacion para la Investigacion Biosanitaria de Andalucia Oriental (FIBAO)

Granada Spain 18014

# Sponsor information

## Organisation

Fundacion para la Investigacion Biosanitaria de Andalucia Oriental (FIBAO) (Spain)

#### Sponsor details

Dr Azpitarte 4, edificio Licinio de la Fuente, 4ª planta Granada Spain 18014 +34 958 02 02 45 pilar.martinez.exts@juntadeandalucia.es

#### Sponsor type

Research organisation

#### Website

http://www.fibao.es/

# Funder(s)

# Funder type

Charity

#### **Funder Name**

The Alicia Koplowitz Foundation (Fundacion Alicia Koplowitz) (Spain)

#### **Funder Name**

Carlos III Institute of Health (Instituto de Salud Carlos III) (Spain) (ref: ETS 07/90902)

# **Results and Publications**

**Publication and dissemination plan**Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**Not provided at time of registration